- E-therapeutics said it had agreed to work with a global 'top five' pharmaceutical company on a project in a specific area of biology associated with neurodegenerative diseases.

Under the 12-month agreement, E-therapeutics said it would use its drug discovery approach to identify novel disease pathways and small molecules. Neurodegeneration occurred when there was progressive loss of structure or function of neurons.

It could lead to a number of debilitating diseases such as Parkinson's, Alzheimer's and Huntington's.

'We are thrilled to be working with one of the largest global pharma companies in an exciting area of disease biology where there is a significant unmet need,' chief executive Ray Barlow said.

At 2:42pm: [LON:ETX] eTherapeutics PLC share price was -0.1p at 2.4p

Story provided by